![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Clinical Trials
Successful Industrial GMP Manufacturing of RIBOXXIM, a Novel and Highly Potent Toll-like 3 Ligand for Immunotherapy of Cancer
RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and ACCINOV, a pharmaceutical establishment for experimental drug product announced the successful...
Clinical Trials
Positive Dupilumab Topline Results From Phase 3 Trial In Uncontrolled Persistent Asthma Announced By Regeneron And Sanofi
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with...
Clinical Trials
Presented in VIVA Late Breaking Clinical Trials Medtronic IN.PACT Admiral DCB Global Two Year Data and IN.PACT SFA Four Year Data
Medtronic plc data announced reinforce the durability and safety of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). ...
Clinical Trials
License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia Completed By RegeneRX
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced that it...
Clinical Trials
Blake Insomnia Therapeutics Inc. Announces Submitting Clinical Trial Application for Phase II Clinical Testing
Blake Insomnia Therapeutics Inc. , a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is excited to...
Clinical Trials
Titan pharmaceuticals receives fda clearance to begin clinical study of parkinson’s disease treatment
Titan Pharmaceuticals, Inc. announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for its ropinirole implant intended for treatment of...
Clinical Trials
Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Osteoarthritis
Symic Bio, a biopharmaceutical company developing novel matrix regulators,announced the treatment of the first patient in the MODIFY2 Phase 2 clinical trial investigating SB-061...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read